MONTREAL, Sept. 7, 2023 /PRNewswire/ - Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment)..

2023年9月7日，蒙特利尔/PRNewswire/-领先的数字健康和人工智能公司Innodem Neurosciences今天宣布，它已与诺华制药加拿大公司（诺华）签署了一项数百万年的多年商业框架协议，以支持其继续努力实现创新的ETNATM技术（眼动神经评估）。。

ETNATM was granted Breakthrough Device designation by the Food & Drug Administration (FDA) last year and this patented, mobile, software technology is embodied in an application that is used in an ongoing observational trial that began in 2021 in collaboration with Novartis. During the trial, ETNATM turns a home tablet into a device capable of capturing in minutes and analyzing through powerful machine learning algorithms several hundreds of functional Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs) that can be used to support clinical management. .

ETNATM去年获得美国食品和药物管理局（FDA）的突破性设备认证，这项获得专利的移动软件技术体现在一项应用程序中，该应用程序用于2021年与诺华合作开展的正在进行的观察性试验。在试验期间，ETNATM将家用平板电脑转变为能够在几分钟内捕获并通过强大的机器学习算法进行分析的设备-数百种功能性眼动生物标志物（EMB）和凝视映射生物标志物（GMB）可用于支持临床管理。 .

This commercial agreement follows the favorable results of the observational trial involving people living with multiple sclerosis (MS). The peer reviewed performance data, which are the subject of a publication in Frontiers in Neurology, can be accessed here: https://www.frontiersin.org/articles/10.3389/fneur.2023.1243594/abstract.

该商业协议遵循涉及多发性硬化症（MS）患者的观察性试验的有利结果。同行评审的表现数据是神经病学前沿出版物的主题，可以在这里访问：https://www.frontiersin.org/articles/10.3389/fneur.2023.1243594/abstract.

The promising data indicates that EMBs and GMBs may have the potential to assist healthcare professionals in detecting subtle signs of clinically significant disease progression including cognition that may not show up using conventional imaging or currently approved blood biomarkers. .

有希望的数据表明，EMB和GMB可能有助于医疗保健专业人员检测临床上显着的疾病进展的微妙迹象，包括可能不会使用常规成像或目前批准的血液生物标志物出现的认知。 .

'In the past year, the non-invasive, mobile ETNATM technology was used by people living with MS during an observational trial where they were able to self-test at home because of the powerful processing capabilities of today's off-the-shelf tablets. With the test results and using AI models, we were able to replicate similar findings of past published academic research papers demonstrating how eye tracking can be used to monitor MS disease status and progression.

“在过去的一年中，MS患者在观察性试验中使用了非侵入性的移动ETNATM技术，由于当今现成平板电脑的强大处理能力，他们能够在家中进行自我测试。通过测试结果和使用AI模型，我们能够复制过去发表的学术研究论文的类似发现，展示如何使用眼动追踪来监测MS疾病状态和进展。

Novartis has recognized Innodem's scalable technology and pending its regulatory clearance, intends to help us bring it to the mainstream with this collaboration,' said Marc Reeves, Co-Founder and Chief Business Officer, Innodem Neurosciences. 'We believe that remote self-testing could improve the efficiencies of the healthcare system and extend this capability to people living with MS residing in rural areas who cannot easily access a specialist,' he added..

诺华公司已经认识到Innodem的可扩展技术，并在获得监管部门的批准之前，打算帮助我们将其带入这一合作的主流，“Innodem Neurosciences的联合创始人兼首席商务官马克·里维斯（Marc Reeves）说他补充说，我们相信远程自我测试可以提高医疗系统的效率，并将这一能力扩展到居住在农村地区的MS患者，他们无法轻易获得专家。。

'Pending regulatory clearance, the new agreement will include a pan-Canadian pilot project in up to -15 sites leading towards a jointly developed commercial plan to make ETNATM readily available to the Canadian MS community,' said Dr. Étienne de Villers-Sidani, cognitive neurologist, main founder and Chief Executive Officer, Innodem Neurosciences..

认知神经病学家Étiennede Villers-Sidani博士说：“在获得监管部门批准之前，新协议将在多达15个地点纳入泛加拿大试点项目，制定共同制定的商业计划，使ETNATM随时可供加拿大MS社区使用。”Innodem Neurosciences的主要创始人兼首席执行官神经学家。。

'This commercial framework agreement with Innodem Neurosciences is an important example of our ongoing commitment to reimagining medicine and improving access to innovation that Canadians deserve,' said Andrea Marazzi, Country President, Novartis Pharmaceuticals Canada Inc. 'By paving the way for a more proactive approach to care in multiple sclerosis, we aim to accelerate the path to much needed solutions that could help improve outcomes for people living with this debilitating disease.'.

“与Innodem Neurosciences签订的这项商业框架协议是我们持续致力于重新设计医学和改善加拿大人应得的创新机会的重要例子，”加拿大诺华制药公司国家总裁Andrea Marazzi说，“为更积极主动地治疗多发性硬化症，我们的目标是加速通往急需的解决方案的道路，这些解决方案可以帮助改善患有这种使人衰弱的疾病的人的预后。

About INNODEM NEUROSCIENCES

关于INNODEM神经科学

Founded in 2016, Innodem Neurosciences has developed patented mobile digital biomarking technology of neurodegenerative diseases such as Multiple Sclerosis, Alzheimer's disease, Parkinson's disease and related disorders, Frontotemporal Dementia and related disorders and Cancer-Related Cognitive Impairment ('chemo brain').

Innodem Neurosciences成立于2016年，开发了神经退行性疾病的专利移动数字生物标记技术，如多发性硬化症，阿尔茨海默病，帕金森病及相关疾病，额颞叶痴呆及相关疾病和癌症相关认知障碍（“化学脑”）。

This novel eye-tracking and cognition testing technology is embodied in an ISO/HIPAA compliant system consisting of an intuitive tablet application connected to a cloud-based AI infrastructure. The app is made up of a series of simple visual tasks that are completed in minutes, where a user's eye movements and gaze patterns are extracted and recorded as hundreds of metrics called Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs).

这种新颖的眼动追踪和认知测试技术体现在符合ISO/HIPAA的系统中，该系统由连接到基于云的AI基础架构的直观平板电脑应用程序组成。该应用程序由一系列简单的视觉任务组成，这些任务在几分钟内完成，用户的眼球运动和凝视模式被提取并记录为数百个称为眼球运动生物标志物（EMB）和凝视映射生物标志物（GMB）的指标。

Innodem's core team, led by cognitive neurologist & CEO Dr. Étienne de Villers-Sidani, is composed of an intersectional group of neuroscientists, software engineers, data scientists, healthcare professionals and serial entrepreneurs. The company's mission is to become the digital leader in mobile applications that can easily extract EMBs & GMBs using its AI-powered ETNATM technology to better serve the needs of the global health system.

Innodem的核心团队由认知神经学家兼首席执行官Eétiennede Villers-Sidani博士领导，由神经科学家，软件工程师，数据科学家，医疗保健专业人员和连续企业家组成的跨部门小组组成。该公司的使命是成为移动应用领域的数字领导者，使用其AI支持的ETNATM技术轻松提取EMB和GMB，以更好地满足全球卫生系统的需求。

For further information, please consult www.innodemneurosciences.com..

有关详细信息，请访问www.innodemneurosciences.com。。

SOURCE Innodem Neurosciences

来源Innodem神经科学